The 10-second takeaway
For the quarter ended March 31 (Q1), Abbott Laboratories beat expectations for both revenue and earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share grew significantly.
Margins grew across the board.
Abbott Laboratories reported revenue of $9.46 billion. The 18 analysts polled by S&P Capital IQ expected to see revenue of $9.36 billion on the same basis. GAAP reported sales were 4.6% higher than the prior-year quarter's $9.04 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $1.03. The 21 earnings estimates compiled by S&P Capital IQ averaged $1 per share on the same basis. GAAP EPS of $0.78 for Q1 were 39% higher than the prior-year quarter's $0.56 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 60.6%, 270 basis points better than the prior-year quarter. Operating margin was 18.3%, 150 basis points better than the prior-year quarter. Net margin was 13.1%, 350 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $9.91 billion. On the bottom line, the average EPS estimate is $1.21.
Next year's average estimate for revenue is $39.93 billion. The average EPS estimate is $5.01.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,559 members rating the stock outperform and 94 members rating it underperform. Among 634 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 618 give Abbott Laboratories a green thumbs-up, and 16 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abbott Laboratories is outperform, with an average price target of $61.61.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Abbott Laboratories. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Abbott Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
This News Explains Why DexCom Is Dropping Today
Shares slide after news breaks that a competitor's product nabs an important reimbursement win.
3 Top Diabetes Stocks to Buy Now
The diabetes market is growing. And these stocks are poised to grow with it.
Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)
ABT earnings call for the period ending September 30, 2017